2-Hydroxydesipramine and desipramine plasma levels

Publisher Website
Google Scholar
Abstract
Thirty-six outpatients aged 20 to 51 with RDC primary major depressive disorder (MUD) completed a 5-week trial of desipramine following a week of single-blind placebo. Five had a past history of hypomanic disorder. For all but one patient, daily dosage at bedtime was constant for the final 4 weeks, with a mean (S.D,) of 168.1 (46.5) mg, Plasma samples drawn at the three final weekly visits were assayed by high-performance liquid chromatography for 2-hydroxydesipramine (2-OH-DMI) and desipramine. Mean (S.D.) plasma levels were 59.8 (30.0) ng/ml for 2-OH-DMI and 142.9 (138.6) ng/ml for desipramine. Thirteen patients (36%) had a final 17-item Hamilton depression rating ≤ 6 and were classified as responders. According to receiver operating characteristics analysis, patients with plasma 2-OH-DMI levels ≥ 58 and = 0.032, Fisher's exact test). Results using an alternate response criterion were similar. These findings suggest that in desipramine-treated outpatients with primary MDD the relationship between therapeutic response and plasma levels is curvilinear for 2-OH-DMI and linear for desipramine.

This publication has 0 references indexed in Scilit: